Circular RNAs modulate cancer drug resistance: advances and challenges

Abstract

Acquired drug resistance is a main factor contributing to cancer therapy failure and high cancer mortality, highlighting the necessity to develop novel intervention targets. Circular RNAs (circRNAs), an abundant class of RNA molecules with a closed loop structure, possess characteristics including high stability, which provide unique advantages in clinical application. Growing evidence indicates that aberrantly expressed circRNAs are associated with resistance against various cancer treatments, including targeted therapy, chemotherapy, radiotherapy, and immunotherapy. Therefore, targeting these aberrant circRNAs may offer a strategy to improve the efficiency of cancer therapy. Herein, we present a summary of the most recently studied circRNAs and their regulatory roles on cancer drug resistance. With the advances in artificial intelligence (AI)-based bioinformatics algorithms, circRNAs could emerge as promising biomarkers and intervention targets in cancer therapy.

Keywords

Drug resistance / CircRNAs / cancer therapy / biomarkers / AI-based bioinformatics algorithms

References

[1] Zhou N,Ling Z.Aryl hydrocarbon receptor sulfenylation promotes glycogenolysis and rescues cancer chemoresistance.J Clin Invest2023;133:e170753 PMCID:PMC10721154

[2] Qiu H,Xu R.Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020.Cancer Commun2021;41:1037-48 PMCID:PMC8504144

[3] Jensen JL,Chan ICC.Clonal hematopoiesis and clinical outcomes in metastatic castration-resistant prostate cancer patients given androgen receptor pathway inhibitors (Alliance A031201).Clin Cancer Res2024;30:4910-9 PMCID:PMC11539927

[4] Qiu C,Tang Y.RGS5⁺ lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism.Drug Resist Updat2024;77:101149

[5] Bordone R,D’Amico R.MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation.Oncogene2024;43:3349-65

[6] Zhou Z,Zheng C.Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy.Acta Pharm Sin B2024;14:4087-101 PMCID:PMC11413680

[7] Barnieh FM,Loadman PM,El-Khamisy SF.Hypoxia-responsive prodrug of ATR inhibitor, AZD6738, selectively eradicates treatment-resistant cancer cells.Adv Sci2024;11:e2403831 PMCID:PMC11425890

[8] Kristensen LS,Hager H.The emerging roles of circRNAs in cancer and oncology.Nat Rev Clin Oncol2022;19:188-206

[9] Wang X,Li J.Mechanisms of non-coding RNA-modulated alternative splicing in cancer.RNA Biol2022;19:541-7 PMCID:PMC9037454

[10] Chen LL.The expanding regulatory mechanisms and cellular functions of circular RNAs.Nat Rev Mol Cell Biol2020;21:475-90

[11] Peng D,Jing B,Zhang Z.A novel protein encoded by circCOPA inhibits the malignant phenotype of glioblastoma cells and increases their sensitivity to temozolomide by disrupting the NONO-SFPQ complex.Cell Death Dis2024;15:616 PMCID:PMC11345445

[12] Tang X,Zhang Y,Gu C.Examining the evidence for mutual modulation between m6A modification and circular RNAs: current knowledge and future prospects.J Exp Clin Cancer Res2024;43:216 PMCID:PMC11297759

[13] Zhou Y,Xu Y,Zhang C.Exosomal circRNAs: a future star in colorectal cancer.Curr Cancer Drug Targets2024;

[14] Xu T,Sun H.Novel insights into the interaction between N6-methyladenosine modification and circular RNA.Mol Ther Nucleic Acids2022;27:824-37 PMCID:PMC8807973

[15] Chen L,Shan G.Circular RNAs in physiology and non-immunological diseases.Trends Biochem Sci2022;47:250-64

[16] Li B,Lu C.circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.Nat Commun2021;12:295 PMCID:PMC7804955

[17] Wang C,Tan S.Characterization of distinct circular RNA signatures in solid tumors.Mol Cancer2022;21:63 PMCID:PMC8889743

[18] Xu C,Okugawa Y.A circulating panel of circRNA biomarkers for the noninvasive and early detection of pancreatic ductal adenocarcinoma.Gastroenterology2024;166:178-90.e16 PMCID:PMC10843014

[19] Xie F,Wang J.deepBase v3.0: expression atlas and interactive analysis of ncRNAs from thousands of deep-sequencing data.Nucleic Acids Res2021;49:D877-83 PMCID:PMC7778966

[20] Ding N,Yang H.A tumor-suppressive molecular axis EP300/circRERE/miR-6837-3p/MAVS activates type I IFN pathway and antitumor immunity to suppress colorectal cancer.Clin Cancer Res2023;29:2095-109 PMCID:PMC10233356

[21] Li J,Shi L.A mammalian conserved circular RNA circLARP1B regulates hepatocellular carcinoma metastasis and lipid metabolism.Adv Sci2024;11:e2305902 PMCID:PMC10787103

[22] Gao X,Li F.Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.Nat Cell Biol2021;23:278-91

[23] Fu M,Xiao M.Extracellular vesicles containing circMYBL1 induce CD44 in adenoid cystic carcinoma cells and pulmonary endothelial cells to promote lung metastasis.Cancer Res2024;84:2484-500

[24] Wong CH,Fung FK.CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein.Mol Cancer2022;21:10 PMCID:PMC8725379

[25] Yang Y,Shao Y.circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer.Cancer Commun2023;43:100-22 PMCID:PMC9859733

[26] Huang B,Ma Q.A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway.Mol Cancer2024;23:34 PMCID:PMC10870583

[27] Ma Q,Huang B.CircARID1A binds to IGF2BP3 in gastric cancer and promotes cancer proliferation by forming a circARID1A-IGF2BP3-SLC7A5 RNA-protein ternary complex.J Exp Clin Cancer Res2022;41:251 PMCID:PMC9389715

[28] Du J,Liao H.CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma.Mol Cancer2022;21:18 PMCID:PMC8762882

[29] Xie M,Jing X.Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation.Mol Cancer2020;19:112 PMCID:PMC7322843

[30] Li R,Jiang J,Shen H.CircRNA CDR1as: a novel diagnostic and prognostic biomarker for gastric cancer.Biomarkers2023;28:448-57

[31] He J,Zeng Z.A potential disease monitoring and prognostic biomarker in cervical cancer patients: the clinical application of circular RNA_0018289.J Clin Lab Anal2020;34:e23340 PMCID:PMC7439420

[32] Tian M,Li T.Reduced expression of circRNA hsa_circ_0003159 in gastric cancer and its clinical significance.J Clin Lab Anal2018;32:e22281 PMCID:PMC6817154

[33] Yao JT,Liu QP.Over-expression of CircRNA_100876 in non-small cell lung cancer and its prognostic value.Pathol Res Pract2017;213:453-6

[34] Zhang X,Wang H.Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway.Mol Cancer2019;18:20 PMCID:PMC6360801

[35] Chen SW,Pei X.Cancer cell-derived exosomal circUSP7 induces CD8⁺ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC.Mol Cancer2021;20:144 PMCID:PMC8576933

[36] Liu J,Bian W,Wei F.circRNA_0001006 predicts prognosis and regulates cellular processes of triple-negative breast cancer via miR-424-5p.Cell Div2023;18:7 PMCID:PMC10186655

[37] Wang X,Huang L.Decreased expression of hsa_circ_001988 in colorectal cancer and its clinical significances.Int J Clin Exp Pathol2015;8:16020-5 PMCID:PMC4730091

[38] Ding M,Yang W,Cui G.Has_circ_0048764 promotes breast cancer progression by sponging miR-578 and regulating HMGA2 expression.Nucleosides Nucleotides Nucleic Acids2023;42:448-63

[39] Dhanyamraju PK.Drug resistance mechanisms in cancers: execution of pro-survival strategies.J Biomed Res2024;38:95-121 PMCID:PMC11001593

[40] Xie R,Huang M.NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer.Cancer Res2023;83:1666-83

[41] Tang H,Wang J.circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer.Mol Cancer2019;18:23 PMCID:PMC6369546

[42] You X,Wang L.Subcellular distribution of RAD23B controls XPC degradation and DNA damage repair in response to chemotherapy drugs.Cell Signal2017;36:108-16

[43] Wang X,Cao G,Shan G.Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance.J Exp Clin Cancer Res2022;41:218 PMCID:PMC9277821

[44] Gong J,Chen Z.CircDCAF8 promotes the progression of hepatocellular carcinoma through miR-217/NAP1L1 axis, and induces angiogenesis and regorafenib resistance via exosome-mediated transfer.J Transl Med2024;22:517 PMCID:PMC11137954

[45] Hua J,Ma L.CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis.Mol Cancer2022;21:123 PMCID:PMC9172052

[46] Zhang P,Wen P,Cui Y.circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma.Mol Ther Nucleic Acids2022;27:293-303 PMCID:PMC8718824

[47] Huang W,Wu J.Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-β signalling.Cell Death Differ2020;27:1709-27 PMCID:PMC7206039

[48] Lin J,Feng H.CircPDIA3/miR-449a/XBP1 feedback loop curbs pyroptosis by inhibiting palmitoylation of the GSDME-C domain to induce chemoresistance of colorectal cancer.Drug Resist Updat2024;76:101097

[49] Pan Z,Zhang J.A novel protein encoded by exosomal circATG4B induces oxaliplatin resistance in colorectal cancer by promoting autophagy.Adv Sci2022;9:e2204513 PMCID:PMC9762280

[50] Wang X,Shi Y.Identification of low-dose radiation-induced exosomal circ-METRN and miR-4709-3p/GRB14/PDGFRα pathway as a key regulatory mechanism in Glioblastoma progression and radioresistance: functional validation and clinical theranostic significance.Int J Biol Sci2021;17:1061-78 PMCID:PMC8040305

[51] Qu H,Yan Q.CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair.J Exp Clin Cancer Res2024;43:122 PMCID:PMC11036759

[52] Lin L,Luo M.CircNOP14 increases the radiosensitivity of hepatocellular carcinoma via inhibition of Ku70-dependent DNA damage repair.Int J Biol Macromol2024;264:130541

[53] Zhang Y,Zhong Z.A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity.J Exp Clin Cancer Res2024;43:52 PMCID:PMC10880370

[54] Chen DL,Sheng H.Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer.Cancer Drug Resist2024;7:9 PMCID:PMC10951830

[55] Hu Z,Zhao Y.Exosome-derived circCCAR1 promotes CD8⁺ T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma.Mol Cancer2023;22:55 PMCID:PMC10024440

[56] Zheng F.CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis.Biomed Pharmacother2020;124:109828

[57] Huang M,Wang Q.Silencing circPVT1 enhances radiosensitivity in non-small cell lung cancer by sponging microRNA-1208.Cancer Biomark2021;31:263-79

[58] Tang YF,Zhang LY.circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC).Mol Cancer2024;23:91 PMCID:PMC11075361

[59] Li H,Jiang X.CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.J Immunother Cancer2022;10:e004029 PMCID:PMC8919471

[60] Marino M,Condorelli RA,La Vignera S.New insights of target therapy: effects of tyrosine kinase inhibitors on male gonadal function: a systematic review.Clin Genitourin Cancer2024;22:102131

[61] Bricker-Anthony R,Lipshutz GS.Staying on target in gene and cell therapy.Mol Ther2024;32:2801-2 PMCID:PMC11403208

[62] Yang WC,Ikawa H.Clinical target volume design and dose in carbon-ion radiation therapy for sinonasal mucosal melanoma.Radiother Oncol2024;200:110511

[63] Bian Y,Bi G.Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis.Redox Biol2024;77:103361 PMCID:PMC11465744

[64] Varshney P,Yadav D.The impacts and changes related to the cancer drug resistance mechanism.Curr Drug Metab2023;24:787-802

[65] Adenis A,Gauthier L.Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.Cancer Chemother Pharmacol2024;94:443-52 PMCID:PMC11420384

[66] Kim HD,Lim HY.Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial.Nat Med2024;30:699-707 PMCID:PMC10957471

[67] Zheng Y,Huang S.Lefamulin overcomes acquired drug resistance via regulating mitochondrial homeostasis by targeting ILF3 in hepatocellular carcinoma.Adv Sci2024;11:e2401789 PMCID:PMC11321631

[68] Chang MH,Han J.Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer.APMIS2009;117:861-9

[69] Tognon CE.Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy.Expert Opin Ther Targets2012;16:33-48

[70] Yang Z,Fu Y.YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8⁺ T cell recruitment.Mol Cancer2024;23:186 PMCID:PMC11378438

[71] Low K,Hills F,Stordal B.The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: a systematic review and pre-clinical study.Cancer Med2024;13:e70248 PMCID:PMC11420655

[72] Liang T,Cheng I.In situ formation of biomolecular condensates as intracellular drug reservoirs for augmenting chemotherapy.Nat Biomed Eng2024;8:1469-82

[73] Han X,Li L.Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial.Signal Transduct Target Ther2024;9:241 PMCID:PMC11402985

[74] Borek WE,Pedicona SF.Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia.EBioMedicine2024;108:105316 PMCID:PMC11424955

[75] Dugo M,Egle D.The immune-related 27-gene signature DetermaIO predicts response to neoadjuvant atezolizumab plus chemotherapy in triple-negative breast cancer.Clin Cancer Res2024;30:4900-9 PMCID:PMC11528202

[76] Akkus E,Ürün Y.Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: insights and perspectives.Cancer Treat Rev2024;130:102818

[77] Ying Q,Shen Y.Small cell lung cancer-an update on chemotherapy resistance.Curr Treat Options Oncol2024;25:1112-23

[78] Lim JKM,Delaidelli A.The eEF2 kinase coordinates the DNA damage response to cisplatin by supporting p53 activation.Cell Death Dis2024;15:501 PMCID:PMC11246425

[79] Mann J,Krautstrunk J.Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse.Int J Cancer2025;156:389-402 PMCID:PMC11578078

[80] Wang P,Chen Z,Hou G.PFKL promotes cell viability and glycolysis and inhibits cisplatin chemosensitivity of laryngeal squamous cell carcinoma.Biochem Biophys Res Commun2024;730:150366

[81] Lu H,Jiang M.Mitochondria-targeted multifunctional nanoprodrugs by inhibiting metabolic reprogramming for combating cisplatin-resistant lung cancer.ACS Nano2024;18:21156-70

[82] Xiao L,Xu H,Li M.Circ_0000395 promotes cell growth, metastasis and oxaliplatin resistance by regulating miR-153-5p/MYO6 in colorectal cancer.Pathol Res Pract2024;260:155476

[83] Liu D,Xu X.Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting.J Hematol Oncol2024;17:84 PMCID:PMC11401258

[84] Hircock C,Raman S.Bridging the care gap: radiation therapy in elderly and frail cancer patients.Curr Opin Support Palliat Care2024;18:276-81

[85] Feng D,Fu B.Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma.Hematology2024;29:2402102

[86] Sharma D,Meena BL,Kapoor R.Exploring the evolving landscape of stereotactic body radiation therapy in hepatocellular carcinoma.J Clin Exp Hepatol2025;15:102386 PMCID:PMC11399579

[87] Liu K,Wang L.Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells.Cancer Lett2024;604:217267 PMCID:PMC11471373

[88] Li C,Han X.Innate immune cells in tumor microenvironment: a new frontier in cancer immunotherapy.iScience2024;27:110750 PMCID:PMC11399700

[89] Chen S,Tian N.The interplay between persistent pathogen infections with tumor microenvironment and immunotherapy in cancer.Cancer Med2024;13:e70154 PMCID:PMC11378724

[90] Liu F,Song B.MAVS-loaded unanchored Lys63-linked polyubiquitin chains activate the RIG-I-MAVS signaling cascade.Cell Mol Immunol2023;20:1186-202 PMCID:PMC10542333

[91] Zhao H,Du D.The RIG-I-like receptor signaling pathway triggered by Staphylococcus aureus promotes breast cancer metastasis.Int Immunopharmacol2024;142:113195

[92] Li J,Zhu J.Gastric cancer derived exosomal THBS1 enhanced Vγ9Vδ2 T-cell function through activating RIG-I-like receptor signaling pathway in a N6-methyladenosine methylation dependent manner.Cancer Lett2023;576:216410

[93] He QQ,Nie L.MAVS integrates glucose metabolism and RIG-I-like receptor signaling.Nat Commun2023;14:5343 PMCID:PMC10475032

[94] Bai M,Deng T,Ba Y.Feasibility and safety of PD-1 blockades among elderly patients with metastatic esophageal squamous cell carcinoma: a real-world study.Drug Des Devel Ther2024;18:4135-51 PMCID:PMC11414636

[95] Yan M,Li X.Transferrin receptor-targeted immunostimulant for photodynamic immunotherapy against metastatic tumors through β-catenin/CREB interruption.Acta Pharm Sin B2024;14:4118-33 PMCID:PMC11413667

[96] Singh A,Vijver SV.Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice.Cancer Immunol Immunother2024;73:16 PMCID:PMC10796629

[97] Zou Y,Chen B.crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer.Drug Resist Updat2024;77:101126

[98] Yang R.Advances and applications of RNA vaccines in tumor treatment.Mol Cancer2024;23:226 PMCID:PMC11463124

[99] Li J,Wang H,Deng H.Exosomal circular RNAs in tumor microenvironment: an emphasis on signaling pathways and clinical opportunities.MedComm2024;5:e70019 PMCID:PMC11586091

[100] Huang X,Zhang J,Tang H.Circular RNAs in breast cancer diagnosis, treatment and prognosis.Oncol Res2023;32:241-9 PMCID:PMC10765117

[101] Cao X,Hou F.ncRNADrug: a database for validated and predicted ncRNAs associated with drug resistance and targeted by drugs.Nucleic Acids Res2024;52:D1393-9 PMCID:PMC10767907

[102] Xie J,Deng X.Circular RNA: a promising new star of vaccine.J Transl Int Med2023;11:372-81 PMCID:PMC10732498

[103] Loan Young T, Chang Wang K, James Varley A, Li B. Clinical delivery of circular RNA: lessons learned from RNA drug development.Adv Drug Deliv Rev2023;197:114826

[104] Deng J,Chen C.Specific intracellular retention of circSKA3 promotes colorectal cancer metastasis by attenuating ubiquitination and degradation of SLUG.Cell Death Dis2023;14:750 PMCID:PMC10654574

[105] Xu J,Liang Y.CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.Signal Transduct Target Ther2020;5:298 PMCID:PMC7762756

[106] Lee KH,Song J,Kim JH.Efficient circular RNA engineering by end-to-end self-targeting and splicing reaction using Tetrahymena group I intron ribozyme.Mol Ther Nucleic Acids2023;33:587-98 PMCID:PMC10457212

[107] Feng Z,Zhou J.An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2⁺/PTBP1⁺ pan-adenocarcinoma.Nat Cancer2024;5:30-46

[108] Zhang Z,Ju X,Zhang P.Advances in engineering circular RNA vaccines.Pathogens2024;13:692 PMCID:PMC11356823

[109] Chen R,Belk JA.Engineering circular RNA for enhanced protein production.Nat Biotechnol2023;41:262-72 PMCID:PMC9931579

[110] Cheng M,Qi S.Development of organ targeting lipid nanoparticles with low immunogenicity and their application in the treatment of pulmonary fibrosis.Angew Chem Int Ed Engl2024;63:e202407398

[111] Ferraresso F,Seadler M.Protein is expressed in all major organs after intravenous infusion of mRNA-lipid nanoparticles in swine.Mol Ther Methods Clin Dev2024;32:101314 PMCID:PMC11382111

[112] Rouatbi N,Costa PM.RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells.J Control Release2024;375:776-87

[113] Palanki R,Bose SK.In utero delivery of targeted ionizable lipid nanoparticles facilitates in vivo gene editing of hematopoietic stem cells.Proc Natl Acad Sci U S A2024;121:e2400783121 PMCID:PMC11317576

[114] Yang H,Qu S.A ROS-responsive lipid nanoparticles release multifunctional hydrogel based on microenvironment regulation promotes infected diabetic wound healing.Adv Sci2024;11:e2403219 PMCID:PMC11578374

[115] Varshney K,Rani A,Ravindra Babu M.Liquid crystalline lipid nanoparticles: emerging trends and applications in skin cancer.Pharm Nanotechnol2024;

[116] Rong J,Yin X.Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma.J Exp Clin Cancer Res2024;43:247 PMCID:PMC11363558

[117] Wang D,Liao X.Oral administration of Robinia pseudoacacia L. flower exosome-like nanoparticles attenuates gastric and small intestinal mucosal ferroptosis caused by hypoxia through inhibiting HIF-1α- and HIF-2α-mediated lipid peroxidation.J Nanobiotechnology2024;22:479 PMCID:PMC11321022

[118] Kassaee SN,Ayoko GA.Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation.Nanomedicine2024;19:2113-33 PMCID:PMC11486133

[119] Wu W,Cao X,Zhao F.Exploring the cellular landscape of circular RNAs using full-length single-cell RNA sequencing.Nat Commun2022;13:3242 PMCID:PMC9187688

[120] Xu C,Wang W. Improving the circularization efficiency, stability and translatability of circular RNA by circDesign. bioRxiv 2023. Available from: https://www.biorxiv.org/content/10.1101/2023.07.09.548293v1. [accessed 26 Mar 2025]

[121] Wesselhoeft RA,Anderson DG.Engineering circular RNA for potent and stable translation in eukaryotic cells.Nat Commun2018;9:2629 PMCID:PMC6035260

[122] Qu L,Shen Y.Circular RNA vaccines against SARS-CoV-2 and emerging variants.Cell2022;185:1728-44.e16 PMCID:PMC8971115

[123] Kim M,Hur S.Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver.Sci Adv2021;7:eabf4398 PMCID:PMC7909888

[124] Jung HN,Lee S,Im HJ.Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging.Theranostics2022;12:7509-31 PMCID:PMC9691360

[125] Saber N,Schiffelers RM.Lipid nanoparticles for nucleic acid delivery beyond the liver.Hum Gene Ther2024;35:617-27

[126] Xu S,Solek NC.Tumor-tailored ionizable lipid nanoparticles facilitate IL-12 circular RNA delivery for enhanced lung cancer immunotherapy.Adv Mater2024;36:e2400307

[127] Zhao Q,Deng H.Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mROS output.Cell2020;183:76-93.e22

[128] Huang G,Zhou Y,Hu T.Recent advances to address challenges in extracellular vesicle-based applications for lung cancer.Acta Pharm Sin B2024;14:3855-75 PMCID:PMC11413688

[129] Rehman FU,Zheng M.Exosomes based strategies for brain drug delivery.Biomaterials2023;293:121949

[130] de Voogt WS, Tanenbaum ME, Vader P. Illuminating RNA trafficking and functional delivery by extracellular vesicles.Adv Drug Deliv Rev2021;174:250-64

[131] Kronstadt SM,Jeyaram A.Extracellular vesicle loading via pH-gradient modification. In: Federico M, Ridolfi B, editors. Extracellular vesicles in diagnosis and therapy. New York: Springer US; 2022. pp. 231-9.

[132] Chao F,Lv L.Extracellular vesicles derived circSH3PXD2A inhibits chemoresistance of small cell lung cancer by miR-375-3p/YAP1.Int J Nanomedicine2023;18:2989-3006 PMCID:PMC10256819

[133] Yu X,Han B.Extracellular vesicle-mediated delivery of circDYM alleviates CUS-induced depressive-like behaviours.J Extracell Vesicles2022;11:e12185 PMCID:PMC8758833

[134] Yang L,Zhang Z.Extracellular vesicle-mediated delivery of circular RNA SCMH1 promotes functional recovery in rodent and nonhuman primate ischemic stroke models.Circulation2020;142:556-74

[135] Zhu Z,Li X.Gut microbiota regulate tumor metastasis via circRNA/miRNA networks.Gut Microbes2020;12:1788891 PMCID:PMC7524358

[136] Liu CX.Circular RNAs: characterization, cellular roles, and applications.Cell2022;185:2016-34

[137] Choi SW.Optimal design of synthetic circular RNAs.Exp Mol Med2024;56:1281-92 PMCID:PMC11263348

[138] Zhang H,Lin A.Algorithm for optimized mRNA design improves stability and immunogenicity.Nature2023;621:396-403 PMCID:PMC10499610

[139] Liang S,Song J.HMCDA: a novel method based on the heterogeneous graph neural network and metapath for circRNA-disease associations prediction.BMC Bioinformatics2023;24:335 PMCID:PMC10494331